FIBROGEN APPOINTS MAYKIN HO, PH.D.

FIBROGEN APPOINTS MAYKIN HO, PH.D., TO BOARD OF DIRECTORS

SAN FRANCISCO, December 6, 2018 FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced the appointment of Maykin Ho, Ph.D., as an independent director to FibroGen s Board of Directors.

We are delighted to welcome Dr. Maykin Ho, an accomplished leader with a great breadth of knowledge in the biotechnology industry, as a new Board

member, said Thomas B. Neff, CEO. Dr. Ho brings extensive experience in global strategy, finance, research, and marketing, and she will be an invaluable advisor as we continue to advance FibroGen s multiple late-stage product

programs, and move closer to the potential commercialization of roxadustat.

Dr. Ho has more than 30 years of experience in the healthcare and

finance industries. She serves on the boards of directors for Agios Pharmaceuticals, Parexel International Corporation, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. Dr. Ho is also a venture partner of

Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. She is a retired partner of the Goldman Sachs Group where she served as senior biotechnology analyst,

co-head of healthcare for global investment research and advisory director for healthcare investment banking. Prior to Goldman Sachs, Dr. Ho held various managerial positions in licensing, strategic

planning, marketing and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company. She was a postdoctoral fellow at Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of

Business, Duke University. Dr. Ho received a Ph.D. in Microbiology and Immunology and a B.S. from the State University of New York, Downstate Medical Center.

I have known and worked with the FibroGen team over the years, said Dr. Ho. FibroGen continues to make progress on a diverse pipeline

and is poised to become a fully integrated company. I am honored to join the Board at such an exciting time in the company s growth and transformation.

FibroGen, Inc., headquartered in San

Francisco, California, with subsidiary offices in Beijing and Shanghai, People s Republic of China, is a leading biopharmaceutical company discovering and developing a pipeline of

first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and

clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity,

completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) currently under review by the National Medical Products Administration (NMPA) in China. Our partner

Astellas submitted a NDA for the treatment of anemia in CKD patients on dialysis in Japan and currently under review by the Pharmaceuticals and Medical Devices Agency (PMDA). Roxadustat

is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF human

monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also

developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.

Forward-Looking Statements

This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the

company s product candidates pamrevlumab and roxadustat, the potential safety and efficacy profile of our product candidates, and our clinical, regulatory plans, and those of our partners. These forward-looking statements include, but are not

limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as may, will , should, on track,

could, expect, plan, anticipate, believe, estimate, predict, potential, continue and similar words, although some forward-looking statements

are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the

enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and our

Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2018 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned

not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Vice President, Investor Relations and Corporate Communications